Neomorph Announces Closing of $100 Million Series B Financing
Financing will support the ongoing Phase 1/2 trial of NEO-811 for the treatment of locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC) and the continued advancement of the company’s broader novel molecular glue degrader pipeline SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) — Neomorph, Inc., a biotechnology company pioneering molecular glue degraders […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.